HALO
Neutral signalScored 2026-10-14 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Halozyme Therapeutics, Inc.
- Nom
- Halozyme Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $14.3B
- Employés
- 423
- PDG
- Helen I. Torley
- Site web
- https://www.halozyme.com
- Marché
- ALNYLGND
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 144 226 titres (~15 546 572,11 $ US)
- Insiders
- Torley HelenPosard Matthew L.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$4,040,907
Avg sell (VWAP, 90d window) $106.27 vs last close $121.84 (+14.7%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$4,040,907 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-08
- Liquidity
- Liquid $306,568,630/day · 20d vol
- Last synced
-
2026-10-17 09:40:27
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-08 | Torley Helen | Sell · S · 10b5-1 | 200 | $110.51 | $22,102 | Form 4 |
| 2026-10-07 | Torley Helen | Sell · S · 10b5-1 | 200 | $113.69 | $22,739 | Form 4 |
| 2026-10-06 | Torley Helen | Sell · S · 10b5-1 | 1,780 | $110.81 | $197,245 | Form 4 |
| 2026-10-01 | Posard Matthew L. | Sell · S · 10b5-1 | 100 | $110.04 | $11,004 | Form 4 |
| 2026-09-16 | Posard Matthew L. | Sell · S · 10b5-1 | 4,000 | $108.99 | $435,964 | Form 4 |
| 2026-09-11 | Torley Helen | Sell · S · 10b5-1 | 4,508 | $107.55 | $484,826 | Form 4 |
| 2026-09-10 | Torley Helen | Sell · S · 10b5-1 | 5,412 | $107.58 | $582,228 | Form 4 |
| 2026-09-09 | Torley Helen | Sell · S · 10b5-1 | 100 | $108.67 | $10,867 | Form 4 |
| 2026-08-19 | Torley Helen | Sell · S · 10b5-1 | 3,200 | $107.77 | $344,848 | Form 4 |
| 2026-08-18 | Torley Helen | Sell · S · 10b5-1 | 9,400 | $104.87 | $985,816 | Form 4 |
| 2026-08-17 | Torley Helen | Sell · S · 10b5-1 | 7,500 | $103.48 | $776,115 | Form 4 |
| 2026-08-10 | Connaughton Bernadette | Sell · S · 10b5-1 | 1,626 | $102.80 | $167,153 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-29 | Gilbert Cisneros | Sale | $1,001 - $15,000 |
| 2026-03-09 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-03-24 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2024-09-09 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-07-12 | Daniel Goldman | Sale (Full) | $15,001 - $50,000 |
| 2022-12-06 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2020-10-22 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-10-19 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-14 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
HALO presents a compelling event-driven setup with strong catalysts — the Dutch court blocking Keytruda SC and the expanded argenx ENHANZE deal — supported by solid operational cash flow and high profit margins.
The first sentence of the analysis written for HALO on 2026-10-14 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $4.0M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $4.0M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Supports a bullish reading. Current ratio 4.66 · operating margin 57%
Suggested stop 104.78, nearest stored support minus 0.5 ATR(14.0% under the last close). Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 83.6% | 84.3% | 76.8% | 78.9% | 81.6% | |
| Ebit Margin | 34.7% | 56.7% | 44.3% | 40.3% | 57.8% | |
| Ebitda Margin | 41.0% | 64.7% | 54.5% | 47.8% | 58.4% | |
| Operating Profit Margin | 57.5% | 54.3% | 40.7% | 40.5% | 62.2% | |
| Pretax Profit Margin | 33.4% | 54.9% | 42.0% | 37.7% | 56.1% | |
| Continuous Operations Profit Margin | 22.7% | 43.7% | 34.0% | 30.6% | 90.8% | |
| Net Profit Margin | 22.7% | 43.7% | 34.0% | 30.6% | 90.8% | |
| Bottom Line Profit Margin | 22.7% | 43.7% | 34.0% | 30.6% | 90.8% | |
| Current Ratio | 4.660 | 7.803 | 6.635 | 5.650 | 7.907 | |
| Quick Ratio | 3.663 | 6.783 | 5.501 | 4.885 | 7.447 | |
| Solvency Ratio | 0.164 | 0.309 | 0.222 | 0.151 | 0.447 | |
| Cash Ratio | 0.756 | 0.833 | 1.052 | 1.791 | 1.013 | |
| Price To Earnings Ratio | 25.492 | 13.660 | 17.352 | 38.446 | 14.059 | |
| Price To Earnings Growth Ratio | -1.037 | 0.212 | 0.395 | -0.797 | 0.070 | |
| Forward Price To Earnings Growth Ratio | -1.037 | 0.212 | 0.395 | -0.797 | 0.070 | |
| Price To Earnings Diluted Ratio | 26.289 | 13.939 | 17.600 | 39.514 | 14.675 | |
| Price To Earnings Diluted Growth Ratio | -1.036 | 0.220 | 0.384 | -0.833 | 0.073 | |
| Price To Book Ratio | 165.224 | 16.666 | 58.181 | 45.857 | 28.714 | |
| Price To Sales Ratio | 5.775 | 5.972 | 5.880 | 11.796 | 12.757 | |
| Price To Free Cash Flow Ratio | 12.512 | 12.946 | 13.063 | 33.091 | 18.979 | |
| Price To Operating Cash Flow Ratio | 12.378 | 12.657 | 12.549 | 32.429 | 18.887 | |
| Debt To Assets Ratio | 0.848 | 0.730 | 0.865 | 0.818 | 0.794 | |
| Debt To Equity Ratio | 43.894 | 4.139 | 17.889 | 8.870 | 4.451 | |
| Debt To Capital Ratio | 0.978 | 0.805 | 0.947 | 0.899 | 0.817 | |
| Long Term Debt To Capital Ratio | 0.978 | 0.805 | 0.947 | 0.898 | 0.800 | |
| Financial Leverage Ratio | 51.734 | 5.672 | 20.681 | 10.845 | 5.608 | |
| Working Capital Turnover Ratio | 1.752 | 1.285 | 1.335 | 0.931 | 0.941 | |
| Operating Cash Flow Ratio | 3.679 | 3.444 | 3.454 | 1.836 | 2.556 | |
| Operating Cash Flow Sales Ratio | 0.467 | 0.472 | 0.469 | 0.364 | 0.675 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.989 | 0.978 | 0.961 | 0.980 | 0.995 | |
| Debt Service Coverage Ratio | 23.340 | 30.036 | 20.531 | 8.874 | 4.263 | |
| Interest Coverage Ratio | 44.279 | 30.477 | 17.992 | 15.786 | 36.660 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 18.007 | 3.349 | |
| Operating Cash Flow Coverage Ratio | 0.304 | 0.318 | 0.259 | 0.159 | 0.342 | |
| Capital Expenditure Coverage Ratio | 93.480 | 44.789 | 25.407 | 49.919 | 205.518 | |
| Dividend Paid And Capex Coverage Ratio | 93.480 | 44.789 | 25.407 | 49.919 | 205.518 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 17.580 | 11.353 | 13.844 | 28.710 | 24.758 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 83.6% | ▼-0.7% | ▲2.6% |
| Ebit Margin | 34.7% | ▼-21.9% | ▼-12.0% |
| Ebitda Margin | 41.0% | ▼-23.6% | ▼-12.2% |
| Operating Profit Margin | 57.5% | ▲3.1% | ▲6.4% |
| Pretax Profit Margin | 33.4% | ▼-21.4% | ▼-11.4% |
| Continuous Operations Profit Margin | 22.7% | ▼-21.1% | ▼-21.7% |
| Net Profit Margin | 22.7% | ▼-21.1% | ▼-21.7% |
| Bottom Line Profit Margin | 22.7% | ▼-21.1% | ▼-21.7% |
| Current Ratio | 4.660 | ▼-3.143 | ▼-1.871 |
| Quick Ratio | 3.663 | ▼-3.119 | ▼-1.992 |
| Solvency Ratio | 0.164 | ▼-0.146 | ▼-0.095 |
| Cash Ratio | 0.756 | ▼-0.077 | ▼-0.333 |
| Price To Earnings Ratio | 25.492 | ▲11.832 | ▲3.690 |
| Price To Earnings Growth Ratio | -1.038 | ▼-1.250 | ▼-0.806 |
| Forward Price To Earnings Growth Ratio | -1.038 | ▼-1.250 | ▼-0.806 |
| Price To Earnings Diluted Ratio | 26.289 | ▲12.350 | ▲3.886 |
| Price To Earnings Diluted Growth Ratio | -1.036 | ▼-1.256 | ▼-0.798 |
| Price To Book Ratio | 165.224 | ▲148.557 | ▲102.295 |
| Price To Sales Ratio | 5.775 | ▼-0.197 | ▼-2.661 |
| Price To Free Cash Flow Ratio | 12.512 | ▼-0.434 | ▼-5.606 |
| Price To Operating Cash Flow Ratio | 12.378 | ▼-0.279 | ▼-5.402 |
| Debt To Assets Ratio | 0.849 | ▲0.119 | ▲0.037 |
| Debt To Equity Ratio | 43.894 | ▲39.755 | ▲28.045 |
| Debt To Capital Ratio | 0.978 | ▲0.172 | ▲0.089 |
| Long Term Debt To Capital Ratio | 0.978 | ▲0.172 | ▲0.092 |
| Financial Leverage Ratio | 51.734 | ▲46.062 | ▲32.826 |
| Working Capital Turnover Ratio | 1.752 | ▲0.467 | ▲0.503 |
| Operating Cash Flow Ratio | 3.679 | ▲0.235 | ▲0.685 |
| Operating Cash Flow Sales Ratio | 0.467 | ▼-0.005 | ▼-0.023 |
| Free Cash Flow Operating Cash Flow Ratio | 0.989 | ▲0.012 | ▲0.009 |
| Debt Service Coverage Ratio | 23.340 | ▼-6.696 | ▲5.931 |
| Interest Coverage Ratio | 44.279 | ▲13.802 | ▲15.240 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▼-4.271 |
| Operating Cash Flow Coverage Ratio | 0.304 | ▼-0.014 | ▲0.028 |
| Capital Expenditure Coverage Ratio | 93.480 | ▲48.691 | ▲9.658 |
| Dividend Paid And Capex Coverage Ratio | 93.480 | ▲48.691 | ▲9.658 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 17.580 | ▲6.227 | ▼-1.669 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $8.07B | $6.06B | $4.88B | $7.79B | $5.66B | |
| Enterprise value | $10.07B | $7.45B | $6.26B | $9.06B | $6.41B | |
| EV / Sales | 7.21x | 7.34x | 7.54x | 13.72x | 14.47x | |
| EV / Op. cash flow | 15.46x | 15.56x | 16.10x | 37.73x | 21.42x | |
| EV / Free cash flow | 15.63x | 15.91x | 16.76x | 38.50x | 21.52x | |
| EV / EBITDA | 17.58x | 11.35x | 13.84x | 28.71x | 24.76x | |
| Net debt / EBITDA | 3.50x | 2.12x | 3.06x | 4.03x | 2.93x | |
| Current ratio | 4.66x | 7.80x | 6.63x | 5.65x | 7.91x | |
| Income quality | 2.06x | 1.08x | 1.38x | 1.19x | 0.74x | |
| Graham number | $5 | $15 | $6 | $6 | $9 | |
| Graham net-net | -$16 | -$6 | -$8 | -$8 | -$1 | |
| Tax burden | 67.9% | 79.7% | 80.8% | 81.2% | 162.0% | |
| Interest burden | 96.3% | 96.9% | 94.9% | 93.6% | 97.1% | |
| Working capital | $648.1M | $946.2M | $633.9M | $608.2M | $809.1M | |
| Invested capital | $2.29B | $1.84B | $1.60B | $1.64B | $817.9M | |
| Return on assets | 12.5% | 21.5% | 16.2% | 11.0% | 36.5% | |
| Operating ROA | 35.0% | 29.0% | 18.9% | 18.2% | 32.8% | |
| Return on tangible assets | 32.9% | 35.7% | 33.4% | 22.8% | 36.5% | |
| Return on equity | 649.2% | 122.1% | 336.0% | 119.0% | 204.5% | |
| Return on invested capital | 23.2% | 22.8% | 16.8% | 12.6% | 25.6% | |
| Return on capital employed | 34.2% | 28.7% | 20.8% | 15.6% | 27.9% | |
| Earnings yield | 3.9% | 7.3% | 5.8% | 2.6% | 7.1% | |
| Free cash flow yield | 8.0% | 7.7% | 7.7% | 3.0% | 5.3% | |
| Capex / Op. cash flow | 1.1% | 2.2% | 3.9% | 2.0% | 0.5% | |
| Capex / Depreciation | 7.9% | 13.2% | 18.0% | 9.7% | 48.6% | |
| Capex / Sales | 0.5% | 1.1% | 1.8% | 0.7% | 0.3% | |
| SG&A / Sales | 14.8% | 15.2% | 18.0% | 21.7% | 11.4% | |
| R&D / Sales | 5.8% | 7.8% | 9.2% | 10.1% | 8.0% | |
| Stock comp / Sales | 3.7% | 4.3% | 4.4% | 3.7% | 4.7% | |
| Intangibles / Total assets | 61.8% | 39.7% | 51.3% | 51.9% | 0.0% | |
| Days sales outstanding | 115d | 111d | 103d | 128d | 75d | |
| Days payables outstanding | 33d | 23d | 22d | 46d | 7d | |
| Operating cycle | 397d | 436d | 345d | 390d | 317d | |
| Cash conversion cycle | 364d | 412d | 323d | 344d | 310d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-13 Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report? Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 2026-10-11 Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $2,191,600.00 in Stock Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $109.58, for a total value of $2,191,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the
- 2026-10-11 Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $2,188,000.00 in Stock Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the business''s stock in a transaction dated Thursday, October 8th. The stock was sold at an average price of $109.40, for a total transaction of $2,188,000.00. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued
- 2026-10-08 HALO Wins Court Order Blocking Merck''s Keytruda SC in Europe Halozyme wins a Dutch court order blocking Merck''s Keytruda SC in eight European markets, strengthening its position in the patent dispute.
- 2026-10-07 HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX Halozyme expands its ENHANZE pact with argenx to eight targets, opening the door to new milestones and royalties as revenue growth accelerates.
- 2026-10-07 Halozyme Wins Injunction Stopping Manufacture and Sale of Merck''s Keytruda SC in Multiple European Markets SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") announced today that the specialized Dutch patent court of the Hague has found Merck to be infringing one of its MDASE patents, EP 2,797,622 (EP622) and ordered Merck''s central European Market Authorization Holder and worldwide packaging and distribution hub MSD BV to refrain from manufacturing, having manufactured, offering, placing on the market and using, or importing or stocking for these purposes, Keytruda SC in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands. The injunction also forbids MSD to facilitate infringement by its affiliates, including by allowing the use of its European Marketing Authorization.
- 2026-10-06 Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology Expanded agreement increases argenx''s exclusive access to ENHANZE® from six to eight targets SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has expanded its global collaboration and license agreement with argenx to develop and commercialize ENHANZE® with two additional exclusive targets. "We are pleased to expand our collaboration with argenx, a recognized leader in immunology, building on the successful development of VYVGART Hytrulo," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme.
- 2026-09-30 Halozyme Announces Appointment of Jim Daly to its Board of Directors SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of James "Jim" Daly to its Board of Directors.
- 2026-09-24 Why Women-Run Companies Deserve a Place in Your Portfolio BMY, HALO, TGT, NEO and ROST stocks show how women-led companies are redefining growth with discipline, agility and results.
- 2026-09-24 Halozyme Therapeutics (NASDAQ:HALO) Reaches New 12-Month High – Here’s Why Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) reached a new 52-week high on Thursday. The stock traded as high as $116.85 and last traded at $112.44, with a volume of 2702748 shares. The stock had previously closed at $115.13. Wall Street Analyst Weigh In A number of brokerages have weighed in on HALO.